Is there a role for early chemotherapy in the management of pituitary adenomas?. Issue 10 (1st October 2016)

• Record Type: Journal Article
• Authors: Lin, Andrew L.; Sum, Melissa W.; DeAngelis, Lisa M.
• Is Part Of: Neuro-oncology. Volume 18:Issue 10(2016:Oct.)
• Page Start: 1350
• Page End: 1356
• Publication Date: 2016-10-01
• Subjects: chemotherapy -- neuro-oncology -- pituitary adenoma -- pituitary carcinoma -- temozolomide; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/now059
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled with standard treatments that include surgical resection, radiotherapy, and agents that modulate hormonal excess. Unfortunately, a subset of patients remains uncontrolled or develops complications from these interventions. For these patients, chemotherapy is an additional treatment option that could improve outcomes. Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas. Its non-overlapping toxicity and ability to induce rapid tumor regression renders it a potentially important adjunctive treatment. In patients with tumors that cannot be optimally addressed with standard treatments, there may be a role for early initiation of temozolomide.